It has been shown that DDR genes and proteins are more highly expressed and activated in SCLC as compared to NSCLC and that blocking these DDR pathways has antitumoral activity in both preclinical [210] and clinical [211] studies, including many different types of cancer. The gene discussed is DDR1; the disease is non-small cell lung carcinoma.